{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:32:12Z","timestamp":1772728332194,"version":"3.50.1"},"reference-count":28,"publisher":"Emerald","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.emerald.com\/insight\/site-policies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,6]]},"abstract":"<jats:sec><jats:title content-type=\"abstract-heading\">Purpose<\/jats:title><jats:p>This audit was conducted on acute psychiatric in\u2010patient wards with the aim of establishing if valproate prescribing in acute mania followed evidence\u2010based guidelines with particular emphasis on formulations used and whether accelerated valproate dosing was employed.<\/jats:p><\/jats:sec><jats:sec><jats:title content-type=\"abstract-heading\">Design\/methodology\/approach<\/jats:title><jats:p>Case notes from 43 (42 percent male) patients admitted with mania and subsequently discharged on valproate were reviewed. Valproate formulation, weight measurement (necessary for dose\u2010calculation in accelerated dosing), initial valproate dose and increments, serum valproate monitoring and other prescribed psychotropic agents were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title content-type=\"abstract-heading\">Findings<\/jats:title><jats:p>Most (95 percent) patients received sodium valproate (epilim chrono\/generic), the remaining received valproate semi\u2010sodium (depakote). All but one patient received antipsychotic medication in combination. Weight was recorded in only four (9 percent) patients. The mean valproate daily dose after the first week was 1,027\u2009mg (sd<jats:italic>=<\/jats:italic>408). It took 29 (sd<jats:italic>=<\/jats:italic>42) days to reach the maximum daily dose (1,426\u2009mg sd<jats:italic>=<\/jats:italic>467) from valproate initiation. Serum levels were monitored in 34 (79 percent) cases, but the mean period between valproate initiation to the first serum level test was 38 (sd<jats:italic>=<\/jats:italic>47) days. A significant positive correlation was found between days taken to reach maximum dose and hospital stay (Spearman's rho<jats:italic>=<\/jats:italic>0.41, <jats:italic>n=<\/jats:italic>43, <jats:italic>p=<\/jats:italic>0.006, two\u2010tailed).<\/jats:p><\/jats:sec><jats:sec><jats:title content-type=\"abstract-heading\">Practical implications<\/jats:title><jats:p>Accelerated valproate dosing was not common practice, which may have resulted in suboptimal efficacy, probably leading to combination treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title content-type=\"abstract-heading\">Originality\/value<\/jats:title><jats:p>This study highlights the need for adequate initial dosing and dose increments when treating manic patients and suggests current practice is not evidence\u2010based. Local prescribing policy and national guidelines' influence on practice are discussed.<\/jats:p><\/jats:sec>","DOI":"10.1108\/09526861211192395","type":"journal-article","created":{"date-parts":[[2012,1,7]],"date-time":"2012-01-07T07:03:34Z","timestamp":1325919814000},"page":"41-52","source":"Crossref","is-referenced-by-count":4,"title":["Valproate in acute mania: is our practice evidence based?"],"prefix":"10.1108","volume":"25","author":[{"given":"Kamini","family":"Vasudev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Macritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"140","reference":[{"key":"key2022021319533673700_b1","doi-asserted-by":"crossref","unstructured":"Allen, M.H., Hirschfeld, R.M., Wozniak, P.J., Baker, J.D. and Bowden, C.L. (2006), \u201cLinear relationship of valproate serum concentration to response and optimal serum levels for acute mania\u201d, American Journal of Psychiatry, Vol. 163 No. 2, pp. 272\u20105.","DOI":"10.1176\/appi.ajp.163.2.272"},{"key":"key2022021319533673700_b2","unstructured":"American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision, American Psychiatric Association, Washington, DC."},{"key":"key2022021319533673700_b3","unstructured":"American Psychiatric Association (2002), \u201cPractice guideline for the treatment of patients with bipolar disorder\u201d, American Journal of Psychiatry, Vol. 159, April, supplement, pp. 1\u201050."},{"key":"key2022021319533673700_b4","doi-asserted-by":"crossref","unstructured":"Australian and New Zealand Journal of Psychiatry (2004), \u201cAustralian and New Zealand Clinical Practice guidelines for the treatment of Bipolar disorder\u201d, Vol. 38 No. 5, pp. 280\u2010305.","DOI":"10.1080\/j.1440-1614.2004.01356.x"},{"key":"key2022021319533673700_b5","unstructured":"British National Formulary (BNF) (2009), available at: www.bnf.org\/bnf\/bnf\/current."},{"key":"key2022021319533673700_b6","doi-asserted-by":"crossref","unstructured":"Bowden, C.L., Brugger, A.M., Swann, A.C., Calabrese, J.R., Janicak, P.G., Petty, F., Dilsaver, S.C., Davis, J.M., Rush, A.J., Small, J.G. and Mania Study Group, The Depakote (1994), \u201cEfficacy of divalproex versus lithium and placebo in the treatment of mania\u201d, Journal of American Medical Association, Vol. 271, pp. 918\u201024.","DOI":"10.1001\/jama.271.12.918"},{"key":"key2022021319533673700_b7","doi-asserted-by":"crossref","unstructured":"Bowden, C.L., Janicak, P.G., Orsulak, P., Swann, A.C., Davis, J.M., Calabrese, J.R., Goodnick, P., Small, J.G., Rush, A.J., Kimmel, S.E., Risch, S.C. and Morris, D.D. (1996), \u201cRelation of serum valproate concentration to response in Mania\u201d, American Journal of Psychiatry, Vol. 153, pp. 765\u201070.","DOI":"10.1176\/ajp.153.6.765"},{"key":"key2022021319533673700_b8","doi-asserted-by":"crossref","unstructured":"Bowden, C.L., Swann, A.C., Calabrese, J.R., Rubenfaer, L.M., Wozniak, P.J., Collins, M.A., Abi\u2010Saab, W., Saltarelli, M., Depakote, E.R. and Study Group, Mania (2006), \u201cA randomized, placebo\u2010controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania\u201d, Journal of Clinical Psychiatry, Vol. 67 No. 10, pp. 1501\u201010.","DOI":"10.4088\/JCP.v67n1003"},{"key":"key2022021319533673700_b9","unstructured":"Bowden, C.L., Calabrese, J.R., McElroy, S.L., Gyulai, L., Wassef, A., Petty, F., Pope, H.G. Jr, Chou, J.C., Keck, P.E. Jr, Rhodes, L.J., Swann, A.C., Hirschfeld, R.M. and Wozniak, P.J. (2000), \u201cA randomized, placebo\u2010controlled 12\u2010month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder\u201d, Archives of General Psychiatry, Vol. 57 No. 5, pp. 481\u20109."},{"key":"key2022021319533673700_b10","doi-asserted-by":"crossref","unstructured":"Canadian Network for Mood and Anxiety Treatments (CANMAT) (2005), \u201cGuidelines for the management of patients with bipolar disorder: consensus and controversies\u201d, Bipolar disorders, Vol. 7, Supplement 3, pp. 5\u201069.","DOI":"10.1111\/j.1399-5618.2005.00219.x"},{"key":"key2022021319533673700_b11","doi-asserted-by":"crossref","unstructured":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT (2009), \u201cGuidelines for the management of patients with bipolar disorder: update\u201d, Bipolar Disorders, Vol. 11 No. 3, pp. 225\u201055.","DOI":"10.1111\/j.1399-5618.2009.00672.x"},{"key":"key2022021319533673700_b12","doi-asserted-by":"crossref","unstructured":"Fisher, C. and Broderick, W. (2003), \u201cSodium valproate or valproate semi\u2010sodium: is there a difference in the treatment of bipolar disorder?\u201d, Psychiatric Bulletin, Vol. 27, pp. 446\u20108.","DOI":"10.1192\/pb.27.12.446"},{"key":"key2022021319533673700_b13","doi-asserted-by":"crossref","unstructured":"Freeman, T.W., Clothier, J.L., Pazzaglia, P., Lesem, M.D. and Swann, A.C. (1992), \u201cA double\u2010blind comparison of valproate and lithium in the treatment of acute mania\u201d, American Journal of Psychiatry, Vol. 149 No. 1, pp. 108\u201011.","DOI":"10.1176\/ajp.149.1.108"},{"key":"key2022021319533673700_b14","doi-asserted-by":"crossref","unstructured":"Goodwin, G.M. (2003), \u201cEvidence\u2010based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology\u201d, Journal of Psychopharmacology, Vol. 17 No. 2, pp. 149\u201073.","DOI":"10.1177\/0269881103017002003"},{"key":"key2022021319533673700_b15","doi-asserted-by":"crossref","unstructured":"Goodwin, G.M. (2009), \u201cEvidence\u2010based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology\u201d, Journal of Psychopharmacology, Vol. 23 No. 4, pp. 346\u201088.","DOI":"10.1177\/0269881109102919"},{"key":"key2022021319533673700_b16","doi-asserted-by":"crossref","unstructured":"Hirschfeld, R.M.A., Allen, M.H., McEvoy, J.P., Keck, P.E. Jr and Russell, J.M. (1999), \u201cSafety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients\u201d, Journal of Clinical Psychiatry, Vol. 60 No. 12, pp. 815\u20108.","DOI":"10.4088\/JCP.v60n1202"},{"key":"key2022021319533673700_b17","doi-asserted-by":"crossref","unstructured":"Hirschfeld, R.M.A., Baker, J.D., Wozniak, P., Tracy, K. and Sommerville, K. (2003), \u201cThe safety and early efficacy of oral\u2010loaded divalproex versus standard\u2010titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder\u201d, Journal of Clinical Psychiatry, Vol. 64, pp. 841\u20106.","DOI":"10.4088\/JCP.v64n0717"},{"key":"key2022021319533673700_b18","unstructured":"Keck, P.E. Jr, McElroy, S.L., Tugrul, K.C. and Bennett, J.A. (1993), \u201cValproate oral loading in the treatment of acute mania\u201d, Journal of Clinical Psychiatry, Vol. 54 No. 8, pp. 305\u20108."},{"key":"key2022021319533673700_b19","unstructured":"McElroy, S.L., Keck, P.E., Stanton, S.P., Tugrul, K.C., Bennett, J.A. and Strakowski, S.M. (1996), \u201cA randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania\u201d, Journal of Clinical Psychiatry, Vol. 57 No. 4, pp. 142\u20106."},{"key":"key2022021319533673700_b20","doi-asserted-by":"crossref","unstructured":"Muller\u2010Oerlinghausen, B., Retzow, A., Henn, F.A., Giedke, H. and Walden, J. (2000), \u201cValproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomised, double\u2010blind, placebo\u2010controlled, multicentre study, European Valproate Mania Study Group\u201d, Journal of Clinical Psychopharmacology, Vol. 20 No. 2, pp. 195\u2010203.","DOI":"10.1097\/00004714-200004000-00012"},{"key":"key2022021319533673700_b21","unstructured":"National Institute for Health and Clinical Excellence (2006), Clinical guidelines on Bipolar Disorder Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care, National Collaborating Centre for Mental Health, London."},{"key":"key2022021319533673700_b22","doi-asserted-by":"crossref","unstructured":"Pope, H.G., McElroy, S.L., Keck, P.E. Jr and Hudson, J.I. (1991), \u201cValproate in the treatment of acute mania\u201d, Archives of General Psychiatry, Vol. 48 No. 1, pp. 62\u20108.","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"key2022021319533673700_b23","doi-asserted-by":"crossref","unstructured":"Soares\u2010Weiser, K., Bravo, V.Y., Beynon, S., Dunn, G., Barbieri, M. and Duffy, S. (2007), \u201cA systematic review and economic model of the clinical effectiveness and cost\u2010effectiveness of interventions for preventing relapse in people with bipolar disorder\u201d, Health Technology Assessment, Vol. 11 No. 39, pp. iii\u2010iv, ix\u2010206.","DOI":"10.3310\/hta11390"},{"key":"key2022021319533673700_b24","doi-asserted-by":"crossref","unstructured":"Tohen, M., Baker, R.W., Altshuler, L.L., Zarate, C.A., Suppes, T., Ketter, T.A., Milton, D.R., Risser, R., Gilmore, J.A., Breier, A. and Tollefson, G.A. (2002), \u201cOlanzapine Versus Divalproex in the treatment of acute mania\u201d, American Journal of Psychiatry, Vol. 159 No. 6, pp. 1011\u20107.","DOI":"10.1176\/appi.ajp.159.6.1011"},{"key":"key2022021319533673700_b25","doi-asserted-by":"crossref","unstructured":"Vasudev, K., Goswami, U. and Kohli, K. (2000), \u201cCarbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder\u201d, Psychopharmacology, Vol. 150 No. 1, pp. 15\u201023.","DOI":"10.1007\/s002130000380"},{"key":"key2022021319533673700_b26","doi-asserted-by":"crossref","unstructured":"Vieta, E. and Sanchez\u2010Moreno, J. (2008), \u201cAcute and long\u2010term treatment of mania\u201d, Dialogues in Clinical Neurosciences, Vol. 10 No. 2, pp. 165\u201079.","DOI":"10.31887\/DCNS.2008.10.2\/evieta"},{"key":"key2022021319533673700_b27","doi-asserted-by":"crossref","unstructured":"Wheeler, A., Robinson, G. and Fraser, A. (2008), \u201cMood stabilizer loading versus titration in acute mania: audit of clinical practice\u201d, Australian and New Zealand Journal of Psychiatry, Vol. 42 No. 11, pp. 955\u201062.","DOI":"10.1080\/00048670802415400"},{"key":"key2022021319533673700_b28","doi-asserted-by":"crossref","unstructured":"Zajecka, J.M., Weisler, R., Sachs, G., Swann, A.C., Wozniak, P. and Sommerville, K.W. (2002), \u201cA comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder\u201d, Journal of Clinical Psychiatry, Vol. 63 No. 12, pp. 1148\u201055.","DOI":"10.4088\/JCP.v63n1210"}],"container-title":["International Journal of Health Care Quality Assurance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.emeraldinsight.com\/doi\/full-xml\/10.1108\/09526861211192395","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.emerald.com\/insight\/content\/doi\/10.1108\/09526861211192395\/full\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.emerald.com\/insight\/content\/doi\/10.1108\/09526861211192395\/full\/html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:29:47Z","timestamp":1753403387000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.emerald.com\/ijhcqa\/article\/25\/1\/41-52\/127642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,6]]}},"alternative-id":["10.1108\/09526861211192395"],"URL":"https:\/\/doi.org\/10.1108\/09526861211192395","relation":{},"ISSN":["0952-6862"],"issn-type":[{"value":"0952-6862","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,6]]}}}